Phase II trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer

Current Oncology

Volumn 19, Issue 2, 2012, Pages

  Young, Scott D ^a   Lafrenie, R M ^b   Clemons, M J ^c  

^a Northeastern Ontario Regional Cancer Centre   (Canada)

^b NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Capecitabine; Docetaxel; Metastatic breast cancer; Metronomic chemotherapy

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CELECOXIB; DOCETAXEL; THYMIDINE PHOSPHORYLASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLURRED VISION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; DYSPNEA; EDEMA; ENZYME LOCALIZATION; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; INFECTION; LEUKOCYTE; LEUKOPENIA; MALE; METASTASIS; METRONOMIC DRUG ADMINISTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAIL DISEASE; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PROTEIN EXPRESSION; RASH; SENSORY NEUROPATHY; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; XEROSTOMIA;

EID: 84859478512     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.879     Document Type: Article

References (40)

1. Vogel CL, Nabholtz JM. Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 1999;4:17-33.
2. Levi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 2006;17:611-21.
3. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010;7:455-65.
4. Smorenburg CH, Sparreboom A, Bontenbal M, Verweij J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur J Cancer 2001;37:2310-23.
5. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/ Taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-19.
6. Méric JB, Rottey S, Olaussen K, et al. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006;59:51-64.
7. Lwanga SK, Lemeshow S. Sample Size Determination in Health Studies. A Practical Manual. Geneva, Switzerland: World Health Organization; 1991.
8. Takeda Y, Yoshizaki I, Nonaka Y, Yanagie H, Matsuzawa A, Eriguchi M. Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2, in vitro and in vivo. Anticancer Drugs 2001;12:691-8.
9. Maher JF, Villalona-Calero MA. Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2002;2:287-93.
10. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S, Tominaga T. Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1995;1:961-4.
11. Moghaddam A, Zhang HT, Fan TP, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci U S A 1995;92:998-1002.
12. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996;73:275-80.
13. Eda H, Fujimoto K, Watanabe S, et al. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333-8.
14. Yamamoto S, Kurebayashi J, Kurosumi M, et al. Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. Cancer Chemother Pharmacol 2001;48:283-8.
15. Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-Ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948-53.
16. Kurosumi M, Tabei T, Suemasu K, et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000;7:945-8.
17. Toi M, Bando H, Horiguchi S, et al. Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 2004;90:2338-43.
18. Nadella P, Shapiro C, Otterson GA, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol 2002;20:2616-23.
19. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase iii trial results. J Clin Oncol 2002;20:2812-23.
20. Miles D, Vukelja S, Moiseyenko V, et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase iii trial. Clin Breast Cancer 2004;5:273-8.
21. Beslija S, Obralic H, Basic A, et al. Randomized trial of sequence vs. combination of capecitabine (x) and docetaxel (t): xt vs. t followed by x after progression as first-line therapy for patients (pts) with metastatic breast cancer (mbc) [abstract 571]. J Clin Oncol 2006;24:. [Available online at: http://www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=40&abstractID=30696; cited February 4, 2012]
22. Tonini G, Schiavon G, Silletta M, Vincenzi B, Santini D. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol 2007;3:183-90.
23. Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004;9:538-45.
24. Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience. Invest New Drugs 2003;21:195-223.
25. Mackey JR, Tonkin KS, Koski SL, et al. Final results of a phase ii clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004;5:287-92.
26. Puglisi F, Cardellino GG, Crivellari D, et al. Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 2008;19:1541-6.
27. Makower D, Wadler S, Haynes H, Schwartz EL. Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin Cancer Res 1997;3:923-9.
28. Bartsch R, Steger GG, Forstner B, et al. Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. BMC Clin Pharmacol 2007;7:7.
29. Layman RM, Thomas DG, Griffith KA, et al. Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 2007;13:4092-7.
30. Mazhar D, Ang R, Waxman J. Cox inhibitors and breast cancer. Br J Cancer 2006;94:346-50.
31. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002;62:1676-81.
32. Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res 2003;23:3215-21.
33. Barnes NL, Warnberg F, Farnie G, et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 2007;96:575-82.
34. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role? Drugs 2007;67:821-45.
35. Cassidy PB, Moos PJ, Kelly RC, Fitzpatrick FA. Cyclooxygenase-2 induction by paclitaxel, docetaxel and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin Cancer Res 2002;8:846-55.
36. Altorki NK, Port JL, Zhang F, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-7.
37. Dirix LY, Ignacio J, Nag S, et al. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. J Clin Oncol 2008;26:1253-9.
38. Ueno T, Chow LW, Toi M. Increases in circulating vegf levels during Cox-2 inhibitor treatment in breast cancer patients. Biomed Pharmacother 2006;60:277-9.
39. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
40. Sauter ER, Qin W, Hewett JE, et al. Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women. BMC Cancer 2008;8:49.